Detail page

Knowledge Web

Person

Mathias Witzens-Harig

Arzt

Name	Mathias Witzens-Harig
Place	Heidelberg (Wirkungsort) Deutschland
Gender	männlich
Academic degree	Priv.-Doz. Dr. med.
Profession	Arzt (characteristic profession)
Variant	M. Witzens-Harig Mathias Witzens- Harig M. Witzens- Harig Matthias Witzens-Harig (falsche Namensform) M. Witzens Mathias Witzens
Related	Ludolf-Krehl-Klinik (bis 2017)
Further information	Oberarzt, Hämatologische Ambulanz, NCT Lymphomsprechstunde, Leukapherese, Verantwortlicher Spenderarzt, Facharzt für Innere Medizin mit Schwerpunkt Hämatologie und internistische Onkologie, Zusatzbezeichnung Palliativmedizin Universitätsklinik Heidelberg
Record type	Person
GND-Identifier	1050736516
Record ID	1050736516
Involved in show all Radiation and Dose-densification of R-CHOP in Aggressive B-cell Lymphoma With Intermediate Prognosis : The UNFOLDER Study Radiation and Dose-densification of R-CHOP in Primary Mediastinal B-cell Lymphoma : Subgroup Analysis of the UNFOLDER Trial A phase II trial to evaluate the combination of pixantrone and obinutuzumab for patients with relapsed aggressive lymphoma: Final results of the prospective, multicentre GOAL trial Correction to: Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B cell non-Hodgkin lymphoma Correction to: Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma Therapy of nodal Follicular Lymphoma (WHO grade 1/2) in clinical stage I/II using response adapted Involved Site Radiotherapy in combination with Obinutuzumab (Gazyvaro) - GAZAI Trial (GAZyvaro and response adapted Involved-site Radiotherapy): a study protocol for a single-arm, non-randomized, open, national, multi-center phase II trial The impact of stem cell transplantation on the natural course of peripheral T-cell lymphoma: a real-world experience HCV load as a possible prognostic factor in patients with HCV-related DLBCL The influence of rituximab-containing chemotherapy on HCV load in patients with HCV-associated non-Hodgkin’s lymphomas In Burkitt lymphoma patients who relapse after induction with a short-intensive chemoimmunotherapy protocol, aggressive salvage chemotherapy therapy is ineffective: a single-center retrospective study Addition of rituximab to CHOP-like chemotherapy in first line treatment of primary mediastinal B-cell lymphoma High-dose chemotherapy and autologous stem cell transplantation of patients with multiple myeloma in an outpatient setting Analysis of prognostic factors in patients with newly diagnosed diffuse large B-cell lymphoma and skeletal involvement Cellular Immunotherapy in B-Cell Malignancy Minimal renal toxicity after Rituximab DHAP with a modified cisplatin application scheme in patients with relapsed or refractory diffuse large B-cell lymphoma A phase I/II trial to evaluate the safety, feasibility and activity of salvage therapy consisting of the mTOR inhibitor Temsirolimus added to standard therapy of Rituximab and DHAP for the treatment of patients with relapsed or refractory diffuse large cell B-Cell lymphoma – the STORM trial Treatment of limited stage follicular lymphoma with Rituximab immunotherapy and involved field radiotherapy in a prospective multicenter Phase II trial-MIR trial Kurzlehrbuch Innere Medizin Development of leukocytoclastic vasculitis in a patient with multiple myeloma during treatment with thalidomide Anti-CD20 antibody as consolidation therapy in a patient with primary plasma cell leukemia after high-dose therapy and autologous stem cell transplantation

Please note

The beta version does not yet contain all functions and information of the DNB portal catalogue. If you are missing information or want to order a medium, please visit the page in the DNB portal catalogue via the following link:

Katalog der Deutschen Nationalbibliothek

Mathias Witzens-Harig

Radiation and Dose-densification of R-CHOP in Aggressive B-cell Lymphoma With Intermediate Prognosis : The UNFOLDER Study

Radiation and Dose-densification of R-CHOP in Primary Mediastinal B-cell Lymphoma : Subgroup Analysis of the UNFOLDER Trial

A phase II trial to evaluate the combination of pixantrone and obinutuzumab for patients with relapsed aggressive lymphoma: Final results of the prospective, multicentre GOAL trial

Correction to: Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B cell non-Hodgkin lymphoma

Correction to: Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma

Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma

The impact of stem cell transplantation on the natural course of peripheral T-cell lymphoma: a real-world experience

HCV load as a possible prognostic factor in patients with HCV-related DLBCL

The influence of rituximab-containing chemotherapy on HCV load in patients with HCV-associated non-Hodgkin’s lymphomas

In Burkitt lymphoma patients who relapse after induction with a short-intensive chemoimmunotherapy protocol, aggressive salvage chemotherapy therapy is ineffective: a single-center retrospective study

Addition of rituximab to CHOP-like chemotherapy in first line treatment of primary mediastinal B-cell lymphoma

High-dose chemotherapy and autologous stem cell transplantation of patients with multiple myeloma in an outpatient setting

Analysis of prognostic factors in patients with newly diagnosed diffuse large B-cell lymphoma and skeletal involvement

Cellular Immunotherapy in B-Cell Malignancy

Minimal renal toxicity after Rituximab DHAP with a modified cisplatin application scheme in patients with relapsed or refractory diffuse large B-cell lymphoma

A phase I/II trial to evaluate the safety, feasibility and activity of salvage therapy consisting of the mTOR inhibitor Temsirolimus added to standard therapy of Rituximab and DHAP for the treatment of patients with relapsed or refractory diffuse large cell B-Cell lymphoma – the STORM trial

Treatment of limited stage follicular lymphoma with Rituximab immunotherapy and involved field radiotherapy in a prospective multicenter Phase II trial-MIR trial

Kurzlehrbuch Innere Medizin

Development of leukocytoclastic vasculitis in a patient with multiple myeloma during treatment with thalidomide

Anti-CD20 antibody as consolidation therapy in a patient with primary plasma cell leukemia after high-dose therapy and autologous stem cell transplantation